Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$648.82K$648.82Kderived−3.4% vs Q4 2023 Net Income-$1.05M-$1.05MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,099,145N/M Operating Cash Flowderived-$673,992N/M Margins · derivedOperating margin-169.4%+17.5 pt vs Q4 2023
Net margin-162.5%+11.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 18, 2025 · 77 d after period end